Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy

Rijkers, Ger T.; Andriessen, S Quirine; Overveld, F. J. van

doi:10.1080/14737140.2019.1677158

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At this moment, and not surprising, 24% of the studies are observational. Yet the importance of gut microbiota (both composition and function) for functionality of the human immune system has become evident in studies on the variable success of checkpoint inhibition therapy for cancer ( Rijkers et al., 2019 ). Moreover, probiotics, in particular Lactobacillus reuteri , has been shown to alleviate the occurrence of colitis, a negative side-effect of checkpoint inhibition therapy (colitis) ( Wang et al., 2019 ).…”

Section: Resultsmentioning

confidence: 99%

Global analysis of clinical trials with probiotics

Dronkers

Ouwehand

Rijkers

2020

Heliyon

Self Cite

View full text Add to dashboard Cite

Over 1,000 clinical studies with probiotics, registered at ClinicalTrials.gov and/or the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization, have addressed over 700 different diseases and conditions. The average size of a clinical trial with probiotics (74 participants) is comparable to the overall average of all studies in ClincialTrials.gov . Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 are the probiotic strains studied most. The exact composition of the product which is used, including the dosage, is not always indicated in the registry. The majority of probiotics studies at ClinicalTrials.gov is registered in the USA or Europe (56%). The data from ICTRP show the rapid expansion of clinical studies with probiotics in Asia, notably Iran and China.

show abstract

Section: Resultsmentioning

confidence: 99%

Global analysis of clinical trials with probiotics

Dronkers

Ouwehand

Rijkers

2020

Heliyon

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to the above-mentioned LBPs approved by FDA, many other LBPs from these companies are currently undergoing the clinical stage. [117][118][119][120][121][122][123][124] Recently, some researchers have observed that some probiotic products do not meet their claimed active counts, which may be due to the inefficient encapsulation methods leading to the decreased strain viability. [125] Thus, appropriate engineering strategies, including the physical, chemical, and genetic methods should be considered and adopted for better clinical use and product manufacturing.…”

Section: Live Biotherapeutic Products (Lbps)mentioning

confidence: 99%

Intestinal Delivery of Probiotics: Materials, Strategies, and Applications

Li,

Wang,

Xiao

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Probiotics with diverse and crucial functions and properties have attracted broad interest from many researchers, who adopt intestinal delivery of probiotics to modulate the gut microbiota. However, the major problems faced for the therapeutic applications of probiotics are the viability and colonization of probiotics during their processing, intake, and subsequent delivery to the gut. The challenges of simple oral delivery (stability, controllability, targeting, etc.) have greatly limited the use of probiotics in clinical therapies. Nanotechnology can endow the probiotics to be delivered to the intestine with improved survival rate and increased resistance to the adverse environment. Additionally, the progress in synthetic biology has created new opportunities for efficiently and purposefully designing and manipulating the probiotics. In this article, we present a brief overview of the types of probiotics for intestinal delivery, the current progress of different probiotic encapsulation strategies, including the chemical, physical, and genetic strategies and their combinations, and the emerging single‐cell encapsulation strategies using nanocoating methods. The action mechanisms of probiotics that are responsible for eliciting beneficial effects are also briefly discussed. Finally, we discuss the therapeutic applications of engineered probiotics, and the future trends toward developing engineered probiotics with advanced features and improved health benefits.This article is protected by copyright. All rights reserved

show abstract